{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:47:16Z","timestamp":1790066836055,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1007\/s10637-018-0687-5","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T03:26:29Z","timestamp":1541561189000},"page":"331-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Phase I\/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Pedro C.","family":"Barata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Mendiratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,7]]},"reference":[{"issue":"1","key":"687_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"687_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS (2018) Metastatic prostate cancer. N Engl J Med 378(7):645\u2013657","journal-title":"N Engl J Med"},{"issue":"15","key":"687_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502\u20131512","journal-title":"N Engl J Med"},{"issue":"15","key":"687_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MHA et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate Cancer. N Engl J Med 351(15):1513\u20131520","journal-title":"N Engl J Med"},{"issue":"6","key":"687_CR5","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756\u20131764","journal-title":"J Clin Oncol"},{"issue":"8","key":"687_CR6","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","volume":"17","author":"PW Kantoff","year":"1999","unstructured":"Kantoff PW, Halabi S, Conaway M et al (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17(8):2506\u20132513","journal-title":"J Clin Oncol"},{"issue":"13","key":"687_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"issue":"21","key":"687_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005","journal-title":"N Engl J Med"},{"issue":"3","key":"687_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"9747","key":"687_CR10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147\u20131154","journal-title":"Lancet"},{"issue":"3","key":"687_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0090-4295(99)00167-3","volume":"54","author":"JL Duque","year":"1999","unstructured":"Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR (1999) Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54(3):523\u2013527","journal-title":"Urology"},{"issue":"9","key":"687_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1200\/JCO.2004.09.142","volume":"22","author":"SF Shariat","year":"2004","unstructured":"Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM (2004) Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 22(9):1655\u20131663","journal-title":"J Clin Oncol"},{"issue":"3","key":"687_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1046\/j.1464-410x.2000.00432.x","volume":"85","author":"A Jones","year":"2000","unstructured":"Jones A, Fujiyama C, Turner K et al (2000) Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 85(3):276\u2013280","journal-title":"BJU Int"},{"issue":"3","key":"687_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0090-4295(99)00156-9","volume":"54","author":"FA Ferrer","year":"1999","unstructured":"Ferrer FA, Miller LJ, Lindquist R et al (1999) Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54(3):567\u2013572","journal-title":"Urology"},{"issue":"13","key":"687_CR15","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","volume":"28","author":"B Escudier","year":"2010","unstructured":"Escudier B, Bellmunt J, Negrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144\u20132150","journal-title":"J Clin Oncol"},{"issue":"13","key":"687_CR16","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","volume":"28","author":"BI Rini","year":"2010","unstructured":"Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137\u20132143","journal-title":"J Clin Oncol"},{"issue":"2","key":"687_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000229787","volume":"77","author":"A Sobrero","year":"2009","unstructured":"Sobrero A, Ackland S, Clarke S et al (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77(2):113\u2013119","journal-title":"Oncology"},{"issue":"5 Suppl 16","key":"687_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","volume":"30","author":"MA Cobleigh","year":"2003","unstructured":"Cobleigh MA, Langmuir VK, Sledge GW et al (2003) A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(5 Suppl 16):117\u2013124","journal-title":"Semin Oncol"},{"issue":"11","key":"687_CR19","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184\u20132191","journal-title":"J Clin Oncol"},{"issue":"17","key":"687_CR20","first-page":"4291","volume":"59","author":"ME McMenamin","year":"1999","unstructured":"McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59(17):4291\u20134296","journal-title":"Cancer Res"},{"issue":"16","key":"687_CR21","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18(16):1926\u20131945","journal-title":"Genes Dev"},{"issue":"5","key":"687_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13","author":"MS Song","year":"2012","unstructured":"Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13(5):283\u2013296","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"22","key":"687_CR23","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271\u20132281","journal-title":"N Engl J Med"},{"issue":"6","key":"687_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast Cancer. N Engl J Med 366(6):520\u2013529","journal-title":"N Engl J Med"},{"issue":"6","key":"687_CR25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514\u2013523","journal-title":"N Engl J Med"},{"issue":"3","key":"687_CR26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3892\/or.2013.2948","volume":"31","author":"M Moriya","year":"2014","unstructured":"Moriya M, Yamada T, Tamura M et al (2014) Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. Oncol Rep 31(3):1109\u20131115","journal-title":"Oncol Rep"},{"issue":"11","key":"687_CR27","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","volume":"66","author":"D Del Bufalo","year":"2006","unstructured":"Del Bufalo D, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66(11):5549\u20135554","journal-title":"Cancer Res"},{"issue":"7","key":"687_CR28","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/bjc.2013.530","volume":"109","author":"K Kruczek","year":"2013","unstructured":"Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi TM, Nabhan C (2013) A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naive castration-resistant prostate cancer. Br J Cancer 109(7):1711\u20131716","journal-title":"Br J Cancer"},{"issue":"16","key":"687_CR29","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2015.65.3154","volume":"34","author":"RR McKay","year":"2016","unstructured":"McKay RR, Zurita AJ, Werner L et al (2016) A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate Cancer after definitive local therapy. J Clin Oncol 34(16):1913\u20131920","journal-title":"J Clin Oncol"},{"issue":"1","key":"687_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2010.11.003","volume":"301","author":"S Wedel","year":"2011","unstructured":"Wedel S, Hudak L, Seibel JM et al (2011) Combined targeting of the VEGFr\/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. Cancer Lett 301(1):17\u201328","journal-title":"Cancer Lett"},{"issue":"14","key":"687_CR31","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1200\/JCO.2014.56.2082","volume":"33","author":"TJ Hobday","year":"2015","unstructured":"Hobday TJ, Qin R, Reidy-Lagunes D et al (2015) Multicenter phase II trial of Temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol 33(14):1551\u20131556","journal-title":"J Clin Oncol"},{"issue":"3","key":"687_CR32","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00280-014-2668-5","volume":"75","author":"JR Merchan","year":"2015","unstructured":"Merchan JR, Qin R, Pitot H et al (2015) Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. Cancer Chemother Pharmacol 75(3):485\u2013493","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18_suppl","key":"687_CR33","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/jco.2007.25.18_suppl.5034","volume":"25","author":"JR Merchan","year":"2007","unstructured":"Merchan JR, Liu G, Fitch T et al (2007) Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 25(18_suppl):5034\u20135034","journal-title":"J Clin Oncol"},{"issue":"3","key":"687_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"687_CR35","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol Off J Am Soc Clin Oncol 26(7):1148\u20131159","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"687_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176\u2013181","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"687_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2013.03.040","volume":"64","author":"AJ Templeton","year":"2013","unstructured":"Templeton AJ, Dutoit V, Cathomas R et al (2013) Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08\/08). Eur Urol 64(1):150\u2013158","journal-title":"Eur Urol"},{"issue":"4","key":"687_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.clgc.2013.05.007","volume":"11","author":"AJ Armstrong","year":"2013","unstructured":"Armstrong AJ, Shen T, Halabi S et al (2013) A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer 11(4):397\u2013406","journal-title":"Clin Genitourin Cancer"},{"issue":"13","key":"687_CR39","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly WK, Halabi S, Carducci M et al (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30(13):1534\u20131540","journal-title":"J Clin Oncol"},{"issue":"2","key":"687_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2012.48.5268","volume":"32","author":"MD Michaelson","year":"2014","unstructured":"Michaelson MD, Oudard S, Ou YC et al (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 32(2):76\u201382","journal-title":"J Clin Oncol"},{"issue":"8","key":"687_CR41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","volume":"14","author":"IF Tannock","year":"2013","unstructured":"Tannock IF, Fizazi K, Ivanov S et al (2013) Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 14(8):760\u2013768","journal-title":"Lancet Oncol"},{"issue":"8","key":"687_CR42","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.2013.50.5305","volume":"32","author":"BI Rini","year":"2014","unstructured":"Rini BI, Bellmunt J, Clancy J et al (2014) Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32(8):752\u2013759","journal-title":"J Clin Oncol"},{"issue":"7","key":"687_CR43","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","volume":"12","author":"S Negrier","year":"2011","unstructured":"Negrier S, Gravis G, Perol D et al (2011) Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 12(7):673\u2013680","journal-title":"Lancet Oncol"},{"issue":"15","key":"687_CR44","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473\u20131482","journal-title":"Lancet Oncol"},{"issue":"2","key":"687_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1008332724977","volume":"11","author":"R Morant","year":"2000","unstructured":"Morant R, Bernhard J, Maibach R et al (2000) Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Ann Oncol 11(2):183\u2013188","journal-title":"Ann Oncol"},{"issue":"1","key":"687_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clgc.2013.09.001","volume":"12","author":"C Nabhan","year":"2014","unstructured":"Nabhan C, Patel A, Villines D, Tolzien K, Kelby SK, Lestingi TM (2014) Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate Cancer patients: final results of a phase II study. Clin Genitourin Cancer 12(1):27\u201332","journal-title":"Clin Genitourin Cancer"},{"issue":"19","key":"687_CR47","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","volume":"14","author":"JS de Bono","year":"2008","unstructured":"de Bono JS, Scher HI, Montgomery RB et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302\u20136309","journal-title":"Clin Cancer Res"},{"issue":"3","key":"687_CR48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","volume":"10","author":"HI Scher","year":"2009","unstructured":"Scher HI, Jia X, de Bono JS et al (2009) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10(3):233\u2013239","journal-title":"Lancet Oncol"},{"issue":"6","key":"687_CR49","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","volume":"70","author":"D Lorente","year":"2016","unstructured":"Lorente D, Olmos D, Mateo J et al (2016) Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer. Eur Urol 70(6):985\u2013992","journal-title":"Eur Urol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0687-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:30:50Z","timestamp":1678559450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0687-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,7]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,15]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0687-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,7]]},"assertion":[{"value":"25 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PB, MC, PM, RG and RD declare no conflict of interest for this study. JG has disclosed to be a consultant or advisor for Genentech, Pfizer; and received research funding from Genentech and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}